GlaxoSmithKline (GSK) ended its three-month hostile pursuit of Human Genome Sciences (HGSI), and the worst of its patent expirations are largely behind it, Barron's reports Like other big European and U.S. pharmaceutical companies, Glaxo, has been cutting costs and reshaping itself into a stronger and more diverse company. Glaxo expects to achieve at least $200M in synergies by 2015. It sees the Human Genome deal adding to its core earnings next year. Additionally a juicy dividend rewarding investors for their patience.
America has no tolerance for wealthy people griping about their financial woes. But they have concerns too.